AlphaGenome 2 targets DNA predictions for specific cell types

Google DeepMind announced AlphaGenome 2 on November 11 as a research model for predicting how DNA variations affect particular cell types and biological states. Rather than relying only on an average picture of a tissue, the model combines a DNA sequence with information about a biological condition. The announcement concerns a research model, not a clinical test.

Access is available through the AlphaGenome API for non-commercial research. Commercial research access is in private preview, so it should not be described as unrestricted commercial availability. The distinction matters for teams considering whether and how they can use the model in a research project.

A genetic change can be important in one kind of cell but have a different effect in another. More focused predictions could help scientists choose which experiments to run and investigate the cell-level mechanisms associated with disease. That is a possible aid to research, not evidence of a new treatment or a demonstrated improvement in patient outcomes.

DeepMind says AlphaGenome and AlphaGenome 2 are for research only and have not been validated or approved for clinical or diagnostic use. Computational predictions still need experimental validation. The announcement, research API availability and source publication were all dated November 11. The laboratory photograph is illustrative and does not show the model's developers or a validated diagnostic procedure.